Molecular underpinning of B-cell anergy

Immunological Reviews

Volumn 237, Issue 1, 2010, Pages 249-263

  Yarkoni, Yuval ^a   Getahun, Andrew ^a   Cambier, John C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

anergy; B cell; PI3K; tolerance

Indexed keywords

ANTIGEN; AUTOANTIGEN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; BREAKPOINT CLUSTER REGION PROTEIN; CALCIUM ION; CD19 ANTIGEN; CD22 ANTIGEN; CD27 ANTIGEN; CD40 LIGAND; CD72 ANTIGEN; CD79B ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CROSS REACTING ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE SHP 1; STROMAL INTERACTION MOLECULE 1;

C57BL 6 MOUSE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CLONAL ANERGY; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MOLECULAR BIOLOGY; MOLECULAR UNDERPINNING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTES; CLONAL ANERGY; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION;

EID: 77955916272     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00936.x     Document Type: Review

References (165)

1. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003 301:1374 1377.
2. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993 177:999 1008.
3. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993 177:1009 1020.
4. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989 337:562 566.
5. Halverson R, Torres RM, Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol 2004 5:645 650.
6. Nossal GJ, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci USA 1980 77:1602 1606.
7. Goodnow CC, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988 334:676 682.
8. Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol 2007 7:633 643.
9. Goodnow CC, Crosbie J, Jorgensen H, Brink RA, Basten A. Induction of self-tolerance in mature peripheral B lymphocytes. Nature 1989 342:385 391.
10. Rui L, Healy JI, Blasioli J, Goodnow CC. ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cytokines to control TLR4-driven plasma cell differentiation. J Immunol 2006 177:5337 5346.
11. Rui L, Vinuesa CG, Blasioli J, Goodnow CC. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat Immunol 2003 4:594 600.
12. Watson ML, et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992 176:1645 1656.
13. Aarons I. Renal immunofluorescence in Nzb-Nzw mice. Nature 1964 203:1080 1081.
14. Shlomchik MJ, Aucoin AH, Pisetsky DS, Weigert MG. Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. Proc Natl Acad Sci USA 1987 84:9150 9154.
15. Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 1991 349:331 334.
16. Eilat D, Hochberg M, Pumphrey J, Rudikoff S. Monoclonal antibodies to DNA and RNA from NZBNZW F1 mice: antigenic specificities and NH2 terminal amino acid sequences. J Immunol 1984 133:489 494.
17. Pewzner-Jung Y, Friedmann D, Sonoda E, Jung S, Rajewsky K, Eilat D. B cell deletion, anergy, and receptor editing in 'knock in' mice targeted with a germline-encoded or somatically mutated anti-DNA heavy chain. J Immunol 1998 161:4634 4645.
18. Wysocki LJ, Sato VL. The strain A anti-p-azophenylarsonate major cross-reactive idiotypic family includes members with no reactivity toward p-azophenylarsonate. Eur J Immunol 1981 11:832 839.
19. Benschop RJ, Aviszus K, Zhang X, Manser T, Cambier JC, Wysocki LJ. Activation and anergy in bone marrow B cells of a novel immunoglobulin transgenic mouse that is both hapten specific and autoreactive. Immunity 2001 14:33 43.
20. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 2005 6:1160 1167.
21. Merrell KT, et al. Identification of anergic B cells within a wild-type repertoire. Immunity 2006 25:953 962.
22. Teague BN, et al. Cutting edge: transitional T3 B cells do not give rise to mature B cells, have undergone selection, and are reduced in murine lupus. J Immunol 2007 178:7511 7515.
23. Roark JH, Bui A, Nguyen KA, Mandik L, Erikson J. Persistence of functionally compromised anti-double-stranded DNA B cells in the periphery of non-autoimmune mice. Int Immunol 1997 9:1615 1626.
24. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001 167:6834 6840.
25. Casellas R, et al. Contribution of receptor editing to the antibody repertoire. Science 2001 291:1541 1544.
26. Adelstein S, et al. Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen. Science 1991 251:1223 1225.
27. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970 169:1042 1049.
28. Kat I, Makdasi E, Fischel R, Eilat D. B-cell anergy is maintained in anti-DNA transgenic NZBNZW mice. Int Immunol 2010 22:101 111.
29. Duty JA, et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009 206:139 151.
30. Fulcher DA, et al. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J Exp Med 1996 183:2313 2328.
31. Fulcher DA, Basten A. Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med 1994 179:125 134.
32. Tough DF, Sprent J. Lifespan of lymphocytes. Immunol Res 1995 14:1 12.
33. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003 21:231 264. (Pubitemid 37174532)
34. Lesley R, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004 20:441 453.
35. Mackay F, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999 190:1697 1710.
36. Oliver PM, Vass T, Kappler J, Marrack P. Loss of the proapoptotic protein, BIM, breaks B cell anergy. J Exp Med 2006 203:731 741.
37. Weintraub JP, Godfrey V, Wolthusen PA, Cheek RL, Eisenberg RA, Cohen PL. Immunological and pathological consequences of mutations in both Fas and Fas ligand. Cell Immunol 1998 186:8 17.
38. Cohen PL, Eisenberg RA. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol Today 1992 13:427 428.
39. Rathmell JC, et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4 + T cells. Nature 1995 376:181 184.
40. Cyster JG, Goodnow CC. Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Immunity 1995 3:691 701.
41. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994 371:389 395.
42. Reth M, et al. The B-cell antigen receptor complex. Immunol Today 1991 12:196 201.
43. Johnson SA, Pleiman CM, Pao L, Schneringer J, Hippen K, Cambier JC. Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases. J Immunol 1995 155:4596 4603.
44. Honda Z, et al. Sequential requirements of the N-terminal palmitoylation site and SH2 domain of Src family kinases in the initiation and progression of FcRI signaling. Mol Cell Biol 2000 20:1759 1771.
45. Yamanashi Y, Kakiuchi T, Mizuguchi J, Yamamoto T, Toyoshima K. Association of B cell antigen receptor with protein tyrosine kinase Lyn. Science 1991 251:192 194.
46. Wechsler RJ, Monroe JG. Src-family tyrosine kinase p55fgr is expressed in murine splenic B cells and is activated in response to antigen receptor cross-linking. J Immunol 1995 154:3234 3244.
47. Lin J, Justement LB. The MB-1B29 heterodimer couples the B cell antigen receptor to multiple src family protein tyrosine kinases. J Immunol 1992 149:1548 1555.
48. Campbell KS, Cambier JC. B lymphocyte antigen receptors (mIg) are non-covalently associated with a disulfide linked, inducibly phosphorylated glycoprotein complex. EMBO J 1990 9:441 448.
49. DeFranco AL, et al. Signal transduction by the B-cell antigen receptor. Ann N Y Acad Sci 1995 766:195 201.
50. van Oers NS, Weiss A. The SykZAP-70 protein tyrosine kinase connection to antigen receptor signalling processes. Semin Immunol 1995 7:227 236.
51. Kurosaki T, Johnson SA, Pao L, Sada K, Yamamura H, Cambier JC. Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med 1995 182:1815 1823.
52. Keshvara LM, Isaacson C, Harrison ML, Geahlen RL. Syk activation and dissociation from the B-cell antigen receptor is mediated by phosphorylation of tyrosine 130. J Biol Chem 1997 272:10377 10381.
53. Pleiman CM, Hertz WM, Cambier JC. Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit. Science 1994 263:1609 1612.
54. Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T. Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 2008 111:1497 1503.
55. Buhl AM, Pleiman CM, Rickert RC, Cambier JC. Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization. J Exp Med 1997 186:1897 1910.
56. Fujimoto M, et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000 13:47 57.
57. Tedder TF, Zhou LJ, Engel P. The CD19CD21 signal transduction complex of B lymphocytes. Immunol Today 1994 15:437 442.
58. Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev 2009 228:253 272.
59. Hikida M, Kurosaki T. Regulation of phospholipase C-2 networks in B lymphocytes. Adv Immunol 2005 88:73 96.
60. Hashimoto A, et al. Involvement of guanosine triphosphatases and phospholipase C-2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. J Exp Med 1998 188:1287 1295.
61. Coughlin JJ, Stang SL, Dower NA, Stone JC. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J Immunol 2005 175:7179 7184.
62. Roose JP, Mollenauer M, Ho M, Kurosaki T, Weiss A. Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes. Mol Cell Biol 2007 27:2732 2745.
63. Leung WH, Tarasenko T, Bolland S. Differential roles for the inositol phosphatase SHIP in the regulation of macrophages and lymphocytes. Immunol Res 2009 43:243 251.
64. Leslie NR, Downes CP. PTEN: The down side of PI 3-kinase signalling. Cell Signal 2002 14:285 295.
65. Fong DC, et al. Mutational analysis reveals multiple distinct sites within Fc receptor IIB that function in inhibitory signaling. J Immunol 2000 165:4453 4462.
66. Songyang Z, Yamanashi Y, Liu D, Baltimore D. Domain-dependent function of the rasGAP-binding protein p62Dok in cell signaling. J Biol Chem 2001 276:2459 2465.
67. Yamanashi Y, et al. Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling. Genes Dev 2000 14:11 16.
68. Fong DC, Malbec O, Arock M, Cambier JC, Fridman WH, Daeron M. Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc receptor IIB during negative regulation of IgE-dependent mouse mast cell activation. Immunol Lett 1996 54:83 91.
69. Malbec O, et al. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc receptor IIB during negative regulation of mast cell activation. J Immunol 1998 160:1647 1158.
70. D'Ambrosio D, Fong DC, Cambier JC. The SHIP phosphatase becomes associated with FcRIIB1 and is tyrosine phosphorylated during 'negative' signaling. Immunol Lett 1996 54:77 82.
71. Daeron M, et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995 3:635 646.
72. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004 41:599 613.
73. Plas DR, Thomas ML. Negative regulation of antigen receptor signaling in lymphocytes. J Mol Med 1998 76:589 595.
74. Rathmell JC, Fournier S, Weintraub BC, Allison JP, Goodnow CC. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. J Exp Med 1998 188:651 659.
75. Healy JI, et al. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 1997 6:419 428.
76. Pao LI, Famiglietti SJ, Cambier JC. Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction. J Immunol 1998 160:3305 3314.
77. Chan VW, Meng F, Soriano P, DeFranco AL, Lowell CA. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 1997 7:69 81.
78. Hibbs ML, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995 83:301 311.
79. Brauweiler A, Merrell K, Gauld SB, Cambier JC. Cutting edge: acute and chronic exposure of immature B cells to antigen leads to impaired homing and SHIP1-dependent reduction in stromal cell-derived factor-1 responsiveness. J Immunol 2007 178:3353 3357.
80. Cooke MP, et al. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med 1994 179:425 438.
81. Vilen BJ, Burke KM, Sleater M, Cambier JC. Transmodulation of BCR signaling by transduction-incompetent antigen receptors: implications for impaired signaling in anergic B cells. J Immunol 2002 168:4344 4451.
82. Vilen BJ, Nakamura T, Cambier JC. Antigen-stimulated dissociation of BCR mIg from IgIg: implications for receptor desensitization. Immunity 1999 10:239 248.
83. Dorner T, Lipsky PE. Signalling pathways in B cells: implications for autoimmunity. Curr Top Microbiol Immunol 2006 305:213 240.
84. Petrie RJ, Schnetkamp PP, Patel KD, Awasthi-Kalia M, Deans JP. Transient translocation of the B cell receptor and Src homology 2 domain-containing inositol phosphatase to lipid rafts: evidence toward a role in calcium regulation. J Immunol 2000 165:1220 1227.
85. Zhao M, Schmitz AA, Qin Y, Di Cristofano A, Pandolfi PP, Van Aelst L. Phosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation. J Exp Med 2001 194:265 274.
86. Bolland S, Ravetch JV. Spontaneous autoimmune disease in FcRIIB-deficient mice results from strain-specific epistasis. Immunity 2000 13:277 285.
87. Yang J, Liang X, Niu T, Meng W, Zhao Z, Zhou GW. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J Biol Chem 1998 273:28199 28207.
88. Frank C, Keilhack H, Opitz F, Zschornig O, Bohmer FD. Binding of phosphatidic acid to the protein-tyrosine phosphatase SHP-1 as a basis for activity modulation. Biochemistry 1999 38:11993 12002.
89. Cornall RJ, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998 8:497 508.
90. Dustin LB, et al. Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation. J Immunol 1999 162:2717 2724.
91. Binstadt BA, et al. SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors. J Biol Chem 1998 273:27518 27523.
92. Pao LI, et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 2007 27:35 48.
93. Blery M, et al. Reconstituted killer cell inhibitory receptors for major histocompatibility complex class I molecules control mast cell activation induced via immunoreceptor tyrosine-based activation motifs. J Biol Chem 1997 272:8989 8996.
94. Browne CD, Del Nagro CJ, Cato MH, Dengler HS, Rickert RC. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity 2009 31:749 760.
95. Lee JO, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999 99:323 334.
96. Gelb MH, Min JH, Jain MK. Do membrane-bound enzymes access their substrates from the membrane or aqueous phase: interfacial versus non-interfacial enzymes. Biochim Biophys Acta 2000 1488:20 27.
97. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 2000 60:7033 7038.
98. Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes CP. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J 2001 357:427 435.
99. Sly LM, Rauh MJ, Kalesnikoff J, Buchse T, Krystal G. SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol 2003 31:1170 1181.
100. Omori SA, et al. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 2006 25:545 557.
101. Kishimoto H, et al. Physiological functions of PTEN in mouse tissues. Cell Struct Funct 2003 28:11 21.
102. Marshall AJ, Krahn AK, Ma K, Duronio V, Hou S. TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma membrane recruitment triggered by the B-cell antigen receptor. Mol Cell Biol 2002 22:5479 5491.
103. Zhang Z, Shen K, Lu W, Cole PA. The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation. J Biol Chem 2003 278:4668 4674.
104. Stoddart A, Ray RJ, Paige CJ. Analysis of murine CD22 during B cell development: CD22 is expressed on B cell progenitors prior to IgM. Int Immunol 1997 9:1571 1579.
105. Torres RM, et al. Identification and characterization of the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule. J Immunol 1992 149:2641 2649.
106. Jin L, McLean PA, Neel BG, Wortis HH. Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med 2002 195:1199 1205.
107. Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev 2009 230:128 143.
108. Duong BH, et al. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J Exp Med 2010 207:173 187.
109. Courtney AH, Puffer EB, Pontrello JK, Yang ZQ, Kiessling LL. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc Natl Acad Sci USA 2009 106:2500 2505.
110. Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med 2002 195:1207 1213.
111. Engel P, Wagner N, Miller AS, Tedder TF. Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med 1995 181:1581 1586.
112. Conrad FJ, Rice JS, Cambier JC. Multiple paths to loss of anergy and gain of autoimmunity. Autoimmunity 2007 40:418 424.
113. Blasioli J, Paust S, Thomas ML. Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22. J Biol Chem 1999 274:2303 2307.
114. Poe JC, Fujimoto M, Jansen PJ, Miller AS, Tedder TF. CD22 forms a quaternary complex with SHIP, Grb2, and Shc: a pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J Biol Chem 2000 275:17420 17427.
115. O'Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999 189:1307 1313.
116. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science 1996 274:798 801.
117. Yakura H, Shen FW, Kaemmer M, Boyse EA. Lyb-2 system of mouse B cells. Evidence for a role in the generation of antibody-forming cells. J Exp Med 1981 153:129 135.
118. Parnes JR, Pan C. CD72, a negative regulator of B-cell responsiveness. Immunol Rev 2000 176:75 85.
119. Kumanogoh A, et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 2000 13:621 631.
120. Adachi T, Flaswinkel H, Yakura H, Reth M, Tsubata T. The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol 1998 160:4662 4665.
121. Wu Y, et al. The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol 1998 8:1009 1017.
122. Li DH, et al. Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis Rheum 2008 58:3192 3204.
123. Pan C, Baumgarth N, Parnes JR. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity 1999 11:495 506.
124. Davis RS, Wang YH, Kubagawa H, Cooper MD. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci USA 2001 98:9772 9777.
125. Hatzivassiliou G, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001 14:277 289.
126. Davis RS. Fc receptor-like molecules. Annu Rev Immunol 2007 25:525 560.
127. Davis RS, Dennis G Jr., Kubagawa H, Cooper MD. Fc receptor homologs (FcRH1-5) extend the Fc receptor family. Curr Top Microbiol Immunol 2002 266:85 112.
128. Srivastava B, Quinn WJ III., Hazard K, Erikson J, Allman D. Characterization of marginal zone B cell precursors. J Exp Med 2005 202:1225 1234.
129. Nieto A, Caliz R, Pascual M, Mataran L, Garcia S, Martin J. Involvement of Fc receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum 2000 43:735 739.
130. Kimberly RP, et al. Diversity and duplicity: human Fc receptors in host defense and autoimmunity. Immunol Res 2002 26:177 189.
131. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001 7:899 905.
132. Dai KZ, et al. The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes Immun 2001 2:263 268.
133. Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol 2003 24:595 602.
134. Kochi Y, et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet 2005 37:478 485.
135. Arm JP, Nwankwo C, Austen KF. Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J Immunol 1997 159:2342 2349.
136. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol 1997 159:5192 5196.
137. Maeda A, Kurosaki M, Ono M, Takai T, Kurosaki T. Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med 1998 187:1355 1360.
138. Ho LH, Uehara T, Chen CC, Kubagawa H, Cooper MD. Constitutive tyrosine phosphorylation of the inhibitory paired Ig-like receptor PIR-B. Proc Natl Acad Sci USA 1999 96:15086 15090.
139. Maeda A, Scharenberg AM, Tsukada S, Bolen JB, Kinet JP, Kurosaki T. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1. Oncogene 1999 18:2291 2297.
140. Kubo T, et al. Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med 2009 206:1971 1982.
141. Torii I, et al. PIR-B-deficient mice are susceptible to Salmonella infection. J Immunol 2008 181:4229 4239.
142. Ujike A, Takeda K, Nakamura A, Ebihara S, Akiyama K, Takai T. Impaired dendritic cell maturation and increased T(H)2 responses in PIR-B(-) mice. Nat Immunol 2002 3:542 548.
143. Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 1997 386:855 858.
144. Borde M, Barrington RA, Heissmeyer V, Carroll MC, Rao A. Transcriptional basis of lymphocyte tolerance. Immunol Rev 2006 210:105 119.
145. Soto-Nieves N, et al. Transcriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance. J Exp Med 2009 206:867 876.
146. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999 286:309 312.
147. Duan L, Reddi AL, Ghosh A, Dimri M, Band H. The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity 2004 21:7 17.
148. Bachmaier K, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000 403:211 216.
149. Kitaura Y, et al. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 2007 26:567 578.
150. Sotelo-Avila C, Gooch WM III. Neoplasms associated with the Beckwith-Wiedemann syndrome. Perspect Pediatr Pathol 1976 3:255 272.
151. Hu RJ, et al. A 2.5-Mb transcript map of a tumor-suppressing subchromosomal transferable fragment from 11p15.5, and isolation and sequence analysis of three novel genes. Genomics 1997 46:9 17.
152. Roos J, et al. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol 2005 169:435 445.
153. Manji SS, et al. STIM1: a novel phosphoprotein located at the cell surface. Biochim Biophys Acta 2000 1481:147 155.
154. Baba Y, et al. Coupling of STIM1 to store-operated Ca2+ entry through its constitutive and inducible movement in the endoplasmic reticulum. Proc Natl Acad Sci USA 2006 103:16704 16709.
155. Stathopulos PB, Li GY, Plevin MJ, Ames JB, Ikura M. Stored Ca2+ depletion-induced oligomerization of stromal interaction molecule 1 (STIM1) via the EF-SAM region: an initiation mechanism for capacitive Ca2+ entry. J Biol Chem 2006 281:35855 35862.
156. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. Orai1 is an essential pore subunit of the CRAC channel. Nature 2006 443:230 233.
157. Vig M, et al. CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science 2006 312:1220 1223.
158. Luik RM, Wu MM, Buchanan J, Lewis RS. The elementary unit of store-operated Ca2+ entry: local activation of CRAC channels by STIM1 at ER-plasma membrane junctions. J Cell Biol 2006 174:815 825.
159. Wu MM, Buchanan J, Luik RM, Lewis RS. Ca2+ store depletion causes STIM1 to accumulate in ER regions closely associated with the plasma membrane. J Cell Biol 2006 174:803 813.
160. Penna A, et al. The CRAC channel consists of a tetramer formed by STIM-induced dimerization of Orai dimers. Nature 2008 456:116 120.
161. Baba Y, Nishida K, Fujii Y, Hirano T, Hikida M, Kurosaki T. Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses. Nat Immunol 2008 9:81 88.
162. Oh-Hora M, et al. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nat Immunol 2008 9:432 443.
163. Picard C, et al. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. N Engl J Med 2009 360:1971 1980.
164. Smyth JT, et al. Phosphorylation of STIM1 underlies suppression of store-operated calcium entry during mitosis. Nat Cell Biol 2009 11:1465 1472.
165. Mond JJ, Feuerstein N, Finkelman FD, Huang F, Huang KP, Dennis G. B-lymphocyte activation mediated by anti-immunoglobulin antibody in the absence of protein kinase C. Proc Natl Acad Sci USA 1987 84:8588 8592.